{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:21:07Z","timestamp":1715998867310},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T00:00:00Z","timestamp":1277337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"\u201cRicerca Sanitaria Finalizzata 2008\u201d Piedmont Region"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anthracyclines are among the most active drugs in breast cancer. Because of excessive cardiotoxicity, their use in combination with trastuzumab has been discouraged in patients with human epidermal growth factor receptor (HER)-2+ metastatic breast cancer. We sought to describe how this treatment paradigm influenced the use of anthracyclines in this patient setting.<\/jats:p><jats:p>We analyzed a multi-institutional database containing the treatment history of 450 patients who received at least one trastuzumab-based regimen for HER-2+ metastatic breast cancer. Patients were considered eligible for anthracyclines for metastatic disease if they were never exposed (NE) or had been previously exposed (PE) to an anthracycline in the neoadjuvant or adjuvant setting and had relapsed after 12 months from the last dose. We then assessed the use of anthracycline-based therapy after failure with the first trastuzumab-based regimen in eligible patients.<\/jats:p><jats:p>Three-hundred twenty-one patients were considered eligible for anthracyclines. In total, 190 eligible patients developing disease progression during the initial trastuzumab-based therapy were analyzed. An anthracycline was administered as first salvage treatment in 14 NE and two PE patients. Another 15 NE and nine PE patients received an anthracycline as a further line of therapy. Of 119 eligible patients who died from breast cancer, only 30 received an anthracycline for metastatic disease.<\/jats:p><jats:p>In conclusion, despite the fact that two thirds of the patients receiving trastuzumab-based therapy for HER-2 metastatic breast cancer are eligible for anthracyclines, these drugs are infrequently used nowadays to treat trastuzumab-refractory disease. A role for these compounds should be redefined in this patient subset.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0016","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T02:51:07Z","timestamp":1277434267000},"page":"665-672","source":"Crossref","is-referenced-by-count":7,"title":["Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer"],"prefix":"10.1093","volume":"15","author":[{"given":"Filippo","family":"Montemurro","sequence":"first","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Rossi","sequence":"additional","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Nol\u00e8","sequence":"additional","affiliation":[{"name":"b European Institute of Oncology (IEO), Department of Medical Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Redana","sequence":"additional","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Donadio","sequence":"additional","affiliation":[{"name":"c Molinette Hospital, Centro Oncologico Subalpino (COES), Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Martinello","sequence":"additional","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verri","sequence":"additional","affiliation":[{"name":"b European Institute of Oncology (IEO), Department of Medical Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cossu","family":"Rocca","sequence":"additional","affiliation":[{"name":"b European Institute of Oncology (IEO), Department of Medical Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Jacomuzzi","sequence":"additional","affiliation":[{"name":"d Mauriziano Hospital, Division of Gynecology, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[{"name":"e Division of Surgical Pathology and Laboratory Medicine, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sapino","sequence":"additional","affiliation":[{"name":"f University of Turin, Department of Biomedical Sciences and Human Oncology, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[{"name":"a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,6,24]]},"reference":[{"key":"2021122207515213000_R1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"2021122207515213000_R2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2007.10.8399","article-title":"Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer","volume":"26","author":"Piccart-Gebhart","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R3","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/1097-0142(19810615)47:12<2798::AID-CNCR2820471207>3.0.CO;2-T","article-title":"Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens","volume":"47","author":"Buzdar","year":"1981","journal-title":"Cancer"},{"issue":"suppl 8","key":"2021122207515213000_R4","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2006.04.022","article-title":"Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer","volume":"33","author":"Jensen","year":"2006","journal-title":"Semin Oncol"},{"key":"2021122207515213000_R5","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Floyd","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"2021122207515213000_R7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122207515213000_R8","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1200\/JCO.2009.22.7504","article-title":"Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines","volume":"27","author":"Trudeau","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122207515213000_R10","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14656566.5.1.81","article-title":"Trastuzumab-based combination therapy for breast cancer","volume":"5","author":"Montemurro","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"2021122207515213000_R12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26\/Breast International Group 03\u201305 study","volume":"27","author":"Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207515213000_R14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0002-9440(10)64952-8","article-title":"Amplification and deletion of topoisomerase II\u03b1 associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer","volume":"156","author":"J\u00e4rvinen","year":"2000","journal-title":"Am J Pathol"},{"key":"2021122207515213000_R15","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2008.21.4791","article-title":"Role of anthracyclines in the treatment of early breast cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R16","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","article-title":"Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer Previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.11-4-318","article-title":"Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy","volume":"11","author":"Montemurro","year":"2006","journal-title":"The Oncologist"},{"issue":"suppl 16","key":"2021122207515213000_R18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(01)90278-7","article-title":"Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart","volume":"28","author":"Schneider","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122207515213000_R19","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1\u03b2 and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"2021122207515213000_R20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/378386a0","article-title":"Multiple essential functions of neuregulin in development","volume":"378","author":"Meyer","year":"1995","journal-title":"Nature"},{"key":"2021122207515213000_R21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","article-title":"HER2 and responsiveness of breast cancer to adjuvant chemotherapy","volume":"354","author":"Pritchard","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207515213000_R22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2021122207515213000_R23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/0008-5472.SABCS-09-62","article-title":"Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study","volume":"69","author":"Slamon","year":"2009","journal-title":"Cancer Res"},{"key":"2021122207515213000_R24","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","article-title":"Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial","volume":"24","author":"Chia","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207515213000_R25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/1078-0432.CCR-08-1113","article-title":"Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase I\/II study","volume":"15","author":"Cortes","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122207515213000_R26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-008-0306-9","article-title":"Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2\/neu positive metastatic breast cancer: A multicenter phase II trial","volume":"117","author":"Stickeler","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2021122207515213000_R27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/annonc\/mdn292","article-title":"Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: Current experience and future strategies","volume":"19","author":"Rayson","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207515213000_R28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122207515213000_R29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/7\/665\/41843309\/oncolo_15_7_665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/7\/665\/41843309\/oncolo_15_7_665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T18:59:45Z","timestamp":1685645985000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/7\/665\/6399410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,24]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,6,24]]},"published-print":{"date-parts":[[2010,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0016","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,7,1]]},"published":{"date-parts":[[2010,6,24]]}}}